David Fogelman MD

David Fogelman, MD

Pediatrics Physical Medicine & Rehabilitation Specialist

Clinical Instructor in Physical Medicine and Rehabilitation, Harvard Medical School

"Underlying all that I do is the fundamental belief that all kids of any age and any level of ability deserve the opportunity to laugh, play, and cause some trouble"

Medical Services

Specialties

  • Pediatric Rehabilitation Medicine

Departments

  • Orthopedic Center

Programs

  • Cerebral Palsy Program
To schedule an appointment: Call 617-355-6021 or Request an Appointment
David Fogelman MD

Philosophy of Care 

Most people, no matter how many physicians they need to see, spend an overwhelming majority of their time working, playing, and living their lives outside of the doctor’s office. As a practitioner of Physical Medicine and Rehabilitation, I am responsible for helping my patients define their relationships with their lives outside of the time they spend in my direct care.


It is an honor, a privilege, and above all a great adventure to work with children and adolescents with special needs. Underlying all that I do is the fundamental belief that all kids of any age and any level of ability deserve the opportunity to laugh, play, and cause some trouble. I know I can help with that.

Experience and Education

Education

Medical School

Mount Sinai School of Medicine, 2009

New York, NY

Internship

Columbia University - St. Luke’s-Roosevelt Hospital Center, 2010

New York, NY

Residency

Spaulding Rehabilitation Hospital, 2013

Boston, MA

Fellowship

Rehabilitation Institute of Chicago, 2015

Chicago, IL

Certifications

  • Orthopedic Surgery

Professional History

David Fogelman, MD began his professional career in engineering school and learned a lot about how to look at the world in terms of cause and effect. He worked in R&D for a Fortune 500 technology company for a few years after college before leaving the field for medical school. Having an engineer’s mind and a doctor’s training really helps him efficiently find what he can do best for his patients and colleagues.

Publications

Publications powered by Harvard Catalyst Profiles
  1. Fogelman D, Zafonte R. Exercise to enhance neurocognitive function after traumatic brain injury. PM R. 2012 Nov; 4(11):908-13.
  2. Borg-Stein JP, Fogelman DJ, Ackerman KE. Exercise, sports participation, and musculoskeletal disorders of pregnancy and postpartum. Semin Neurol. 2011 Sep; 31(4):413-22.
  3. Fogelman DR, Wolff RA, Kopetz S, Javle M, Bradley C, Mok I, Cabanillas F, Abbruzzese JL. Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. Anticancer Res. 2011 Apr; 31(4):1417-20.
  4. Javle MM, Shroff RT, Xiong H, Varadhachary GA, Fogelman D, Reddy SA, Davis D, Zhang Y, Wolff RA, Abbruzzese JL. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer. 2010; 10:368.
  5. Slade JH, Alattar ML, Fogelman DR, Overman MJ, Agarwal A, Maru DM, Coulson RL, Charnsangavej C, Vauthey JN, Wolff RA, Kopetz S. Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. Clin Colorectal Cancer. 2009 Oct; 8(4):225-30.
  6. Fogelman DR, Kopetz S, Eng C. Emerging drugs for colorectal cancer. Expert Opin Emerg Drugs. 2008 Dec; 13(4):629-42.
  7. Blazer DG, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, Fogelman D, Eng C, Chang DZ, Wang H, Zorzi D, Ribero D, Ellis LM, Glover KY, Wolff RA, Curley SA, Abdalla EK, Vauthey JN. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008 Nov 20; 26(33):5344-51.
  8. Overman MJ, Kopetz S, Wen S, Hoff PM, Fogelman D, Morris J, Abbruzzese JL, Ajani JA, Wolff RA. Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. Cancer. 2008 Oct 15; 113(8):2038-45.
  9. Overman MJ, Fogelman D, Al-Kali A, Crane CH, Evans D, Abdalla EK, Pisters P, Kopetz S, Eng C, Wolff RA. Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 cases. Clin Colorectal Cancer. 2008 Sep; 7(5):338-42.
  10. Fine RL, Fogelman DR, Schreibman SM, Desai M, Sherman W, Strauss J, Guba S, Andrade R, Chabot J. The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol. 2008 Jan; 61(1):167-75.
  11. Show all
  12. Fine RL, Shah SS, Moulton TA, Yu IR, Fogelman DR, Richardson M, Burris HA, Samuels BL, Assanasen C, Gorroochurn P, Hibshoosh H, Orjuela M, Garvin J, Goldman FD, Dubovsky D, Walterhouse D, Halligan G. Androgen and c-Kit receptors in desmoplastic small round cell tumors resistant to chemotherapy: novel targets for therapy. Cancer Chemother Pharmacol. 2007 Mar; 59(4):429-37.
  13. Fogelman DR, Chen J, Chabot JA, Allendorf JD, Schrope BA, Ennis RD, Schreibman SM, Fine RL. The evolution of adjuvant and neoadjuvant chemotherapy and radiation for advanced pancreatic cancer: from 5-fluorouracil to GTX. Surg Oncol Clin N Am. 2004 Oct; 13(4):711-35, x.
To schedule an appointment: Call 617-355-6021 or Request an Appointment

Locations

We are grateful to have been ranked #1 on U.S. News & World Report's list of the best children's hospitals in the nation for the third year in a row, an honor we could not have achieved without the patients and families who inspire us to do our very best for them. Thanks to you, Boston Children's is a place where we can write the greatest children's stories ever told.”
- Sandra L. Fenwick, President and CEO

Boston Children's Hospital 300 Longwood Avenue, Boston, MA 02115 617-355-6000 | 800-355-7944

Close